Attending Biotech and Pharma
- Attending Biotech and Pharma logo and links
We are at present carefully building the small molecule and biologics speaker tracks for BOS cmc 2012 and plan to release the programmes during Quarter 1, 2012. To provide a flavour of the focus of presentations please look below.
BOS cmc 2012 small molecule track
Our small molecule track for 2012 will cover early CMC activities into later stages of clinical CMC development. Presentations will cover drug substance outsourcing, drug product formulation strategies and pharmaceutical developability (utlising QbD), outsouring CMC regulatory requirements for NCE's, oral delivery of peptides and future trends shaping CMC outsourcing. The programme will focus largely on NCE (New Chemical Entity) CMC challenges.
BOS cmc 2012 biologics track
The planned programme for our biologics track has been developed to address key issues in biologics CMC outsourcing and will cover topics including; trends and future challenges in biologics drug product outsourcing, challenges and opportunities presented by outsourcing analytical and formulation assays, CRO/CMO selection and relationship management strategies for drug product formulation, prefered supplier partnerships from a pharma perspective and technology transfer challenges as a compound progresses into later stage clinical trials.
BOS cmc 2012 closing plenary session
Uniting the small molecule and biologics speaker tracks the closing plenary will include presentations from pharma, biotech and the CRO/CMO community examining perspective and approaches to encourage innovation in CMC outsourcing.
To view the BOS cmc 2011 speaker programmes please click here